Insider Buying: Septerna, Inc. (NASDAQ:SEPN) Director Buys 41,355 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz acquired 41,355 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were purchased at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the purchase, the director now directly owns 104,101 shares in the company, valued at approximately $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alan Ezekowitz also recently made the following trade(s):

• On Tuesday, March 4th, Alan Ezekowitz purchased 7,491 shares of Septerna stock. The shares were purchased at an average price of $6.35 per share, for a total transaction of $47,567.85.

Septerna Trading Down 8.7 %

SEPN stock traded down $0.56 during trading on Monday, hitting $5.87. The stock had a trading volume of 769,009 shares, compared to its average volume of 590,636. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The business's 50-day moving average price is $14.10.

Analysts Set New Price Targets

SEPN has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target on the stock. Wells Fargo & Company cut Septerna from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $43.00 to $14.00 in a research report on Tuesday, February 18th. Finally, TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They set a "buy" rating on the stock.

Remove Ads

Institutional Trading of Septerna

Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna during the fourth quarter worth $25,000. New York State Common Retirement Fund purchased a new stake in Septerna during the 4th quarter valued at about $32,000. Legal & General Group Plc acquired a new stake in Septerna in the 4th quarter valued at about $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna in the 4th quarter worth approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna in the 4th quarter worth approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.